Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7452620 | 0.79 | CDK2 (0.47) | NUDT1 | |
| SCHEMBL7453052 | 0.75 | CCNA2 (0.36) | NUDT1 | |
| SCHEMBL534997 | 0.65 | PNP (0.59) | — | |
| SCHEMBL2634662 | 0.65 | NUDT1 (0.61) | PDPK1GDANUDT1 | |
| SCHEMBL140621 | 0.63 | ALDH1A1 (0.50) | — | |
| SCHEMBL31561489 | 0.62 | PDPK1 (0.45) | PDPK1GDAADORA2A | |
| SCHEMBL16513157 | 0.61 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL1705024 | 0.61 | PDPK1 (0.44) | PDPK1GDA | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.61 | PDPK1 (1.00) | PDPK1GDAADORA2A | |
| SCHEMBL5133438 | 0.61 | ADORA2A (0.55) | PDPK1GDAADORA2ANUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884886-B2 | Disulfide masked prodrug compositions and methods | MERCK SHARP & DOHME (US) | 2018-02-06 | — | — | US | claimed |
| US-9192621-B2 | Esters and malonates of SATE prodrugs | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-24 | — | — | US | claimed |
| WO-2015095305-A1 | PRODUCTION OF CYCLIC PHOSPHATE, PHOSPHORAMIDATE, THIOPHOSPHATE, AND PHOSPHONATE NUCLEOSIDE COMPOUNDS | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| US-8076310-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-12-13 | — | — | US | claimed |
| US-20110009606-A1 | Synthesis of 2',3' - and 3',5' -cyclic phosphate mono-and oligonucleotides | CHEMGENES CORPORATION | 2011-01-13 | — | — | US | claimed |
| WO-2009120358-A1 | OLIGOMER-NITROGENOUS BASE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2009-10-01 | — | — | WO | claimed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | claimed |
| US-5663159-A | VIRICIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-09-02 | — | — | US | claimed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| EP-1301519-B2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3539546-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0502447-A1 | Tetrahydrofuran intermediates | Bristol-Myers Squibb Company (US) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009606-A1 | Synthesis of 2',3' - and 3',5' -cyclic phosphate mono-and oligonucleotides | ITPA, NT5C2, NT5C3B | PDPK1 2794/4885GDA 621/4885ADORA2A 369/4885 |
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | POLRMT, POLM, NSUN2 | PDPK1 1900/4885GDA 5/4885ADORA2A 932/4885 |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | PDPK1 112/4885GDA 444/4885ADORA2A 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.